Translational crossroads for biomarkers

Clinical Cancer Research

Volumn 11, Issue 17, 2005, Pages 6103-6108

  Bast Jr , Robert C ^a   Lilja, Hans ^b   Urban, Nicole ^c   Rimm, David L ^d   Fritsche, Herbert ^a   Gray, Joe ^e   Veltri, Robert ^g   Klee, George ^j   Allen, Andrew ^k   Kim, Nam ^f   Gutman, Steven ^h   Rubin, Mark A ^l   Hruszkewycz, Andrew ⁱ  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^f diaDexus Inc   (United States)

^g JOHNS HOPKINS HOSPITAL   (United States)

^h CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j MAYO CLINIC   (United States)

^k ABBOTT LABORATORIES   (United States)

^l DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

BREAST CANCER; CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; COMPUTER; DEVELOPMENT; DISEASE MARKER; DRUG RESPONSE; EARLY DIAGNOSIS; EVALUATION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE NEED; HUMAN; INDUSTRY; INFORMATION DISSEMINATION; LABORATORY TEST; NATIONAL CANCER INSTITUTE; NATIONAL HEALTH SERVICE; OVARY CANCER; PATIENT MONITORING; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; REFERENCE VALUE; REVIEW; TECHNOLOGY; UNIVERSITY; VALIDATION PROCESS;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 24344491449     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2213     Document Type: Review

References (16)

1. Pettersson K, Piironen T, Seppälä M, et al. Free and complexed prostate-specific antigen (PSA): In vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-a1-anti-chymotrypsin complex. Clin Chem 1995;41: 1480-8.
2. Aus G, Becker C, Franzen S, Lilja H, Lodding P, Hugosson J. Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio. Eur Urol 2004;45:160-5.
3. Piironen T, Villoutreix BO, Becker C, et al. Determination and analysis of antigenic epitopes of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) using synthetic peptides and computer modeling. Protein Sci 1998;7:259-69.
4. Haese A, Graefen M, Becker C, et al. The role of human glandular kallikrein 2 (hK2) for prediction of pathologically organ-confined prostate cancer. Prostate 2003;54:181-6.
5. Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695-700.
6. McIntosh MW, Drescher C, Urban N, Scholler N, Hellstrom I, Hellstrom K. Combining CA125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol 2004 Oct;95:9-15.
7. McIntosh MW, Pepe MS. Combining several screening test; optimality of the risk score. Biometrics 2002 Sep;58:657-64.
8. Etzioni R, Kooperberg C, Pepe M, Smith R, Gann PH. Combining biomarkers to detect disease with application to prostate cancer. Biostatistics 2003 Oct;4: 523-38.
9. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8:1323-7.
10. Camp RL, Dolled-Filhart M, King BL, Rimm DL. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res 2003;63:1445-8.
11. Rubin MA, Zerkowski MP, Camp RL, et al. Quantitative determination of expression of the prostate cancer protein α-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements. Am J Pathol 2004;164:831-40.
12. DiVito KA, Charette LA, Rimm DL, Camp RL. Long-term preservation of antigenicity on tissue microarrays. Lab Invest 2004;84:1071-8.
13. Shi S-R, Cote RJ, Taylor CR. Antigen retrieval techniques: current perspectives. J Histochem Cytochem 2001;49:931-8.
14. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-91.
15. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-61.
16. Katton MW. Judging new markers by their ability to improve predictive acuracy. J Natl Cancer Inst 2003; 95:634-5.